Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rocmaline
- Development stage
- Unknown
- Lead developer
- FRiLAB
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rocmaline is an oral combination of L-arginine and malic acid developed by FRiLAB. It is indicated for the treatment of asthenia (fatigue), presumed functional liver disorders, and metabolic support, and is also promoted as a sexual potentiator to help maintain erectile function. L-arginine acts as a precursor for nitric oxide synthesis, promoting vasodilation and blood flow, and participates in the urea cycle to aid in detoxification. Malic acid is a key intermediate in the tricarboxylic acid (TCA) cycle, supporting cellular energy production and reducing muscle fatigue.
- Brand names
- Rocmaline
- Other names
- arginine + malic acidl-arginine + malic acid
02
Targets
ARG1 (Arginase 1)ME (Protocadherin beta-11)NOS1 (nNOS)
Beyond the preview
Go deeper on Rocmaline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rocmaline.